Sökning: onr:"swepub:oai:DiVA.org:uu-437370" >
Peptide Receptor Ra...
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE : Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
-
- Jahn, Ulrika (författare)
- Uppsala universitet,Radiologi
-
- Ilan, Ezgi (författare)
- Uppsala universitet,Radiologi,Institutionen för immunologi, genetik och patologi
-
- Sandström, Mattias (författare)
- Uppsala universitet,Radiologi,Institutionen för immunologi, genetik och patologi
-
visa fler...
-
- Lubberink, Mark (författare)
- Uppsala universitet,Radiologi,Institutionen för immunologi, genetik och patologi
-
- Garske-Román, Ulrike, 1963- (författare)
- Uppsala universitet,Radiologi,Experimentell och klinisk onkologi,Medical Imaging Centre, Uppsala University Hospital
-
- Sundin, Anders, 1954- (författare)
- Uppsala universitet,Radiologi,Medical Imaging Centre, Uppsala University Hospital
-
visa färre...
-
(creator_code:org_t)
- 2021-02-25
- 2021
- Engelska.
-
Ingår i: Cancers. - : MDPI. - 2072-6694. ; 13:5
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.mdpi.com...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- Dosimetry during peptide receptor radionuclide therapy (PRRT) has mainly focused on normal organs and less on the tumors. The absorbed dose in one target tumor per patient and several response related factors were assessed in 23 pancreatic neuroendocrine neoplasms (P-NENs) and 25 small-intestinal NEN (SI-NENs) during PRRT with 177Lu-DOTATATE. The total administered activity per patient was (mean ± standard error of mean (SEM) 31.8 ± 1.9 GBq for P-NENs and 36 ± 1.94 GBq for SI-NENs. The absorbed tumor dose was 143.5 ± 2 Gy in P-NENs, 168.2 ± 2 Gy in SI-NENs. For both NEN types, a dose-response relationship was found between the absorbed dose and tumor shrinkage, which was more pronounced in P-NENs. A significant drop in the absorbed dose per cycle was shown during the course of PRRT. Tumor vascularization was higher in P-NENs than in SI-NENs at baseline but equal post-PRRT. The time to progression (RECIST 1.1) was similar for patients with P-NEN (mean ± SEM 30 ± 1 months) and SI-NEN (33 ± 1 months). In conclusion, a dose response relationship was established for both P-NENs and SI-NENs and a significant drop in the absorbed dose per cycle was shown during the course of PRRT, which warrants further investigation to understand the factors impacting PRRT to improve personalized treatment protocol design.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- 177Lu-DOTATATE
- PRRT
- dosimetry
- low-dose-radiation
- pancreatic NEN
- radionuclide therapy
- small intestinal NEN
- theranostics
- vascularization
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Cancers
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas